US Patent Issued to The Board of Trustees of the Leland Stanford Junior University, Stanford, California on Feb. 3 for "Crispr-based FOXP3 gene engineered t cells and hematopoietic stem cell precursors to treat IPEX syndrome patients" (California Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,311, issued on Feb. 3, was assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, California (Stanford, Calif.).

"Crispr-based FOXP3 gene engineered t cells and hematopoietic stem cell precursors to treat IPEX syndrome patients" was invented by Rosa Bacchetta (Menlo Park, Calif.), Maria-Grazia Roncarolo (Menlo Park, Calif.), Matthew Porteus (Stanford, Calif.) and Marianne Goodwin (Redwood City, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Compositions and methods are provided relating to FOXP3 gene edited hematopoietic cells, include hematopoietic stem and progenitor cells, lymphoid progenitor cells, and CD4+ T...